参考文献:
[1]HUANG ZQ. A historical perspective of surgical treatment of liver cancer[J]. Chin J Dig Surg, 2010, 9(1): 1-3.(in Chinese)
黄志强. 肝脏治疗的历史和现状[J]. 中华消化外科杂志, 2010, 9(1): 1-3.
[2]XIA SS, QIU FZ. Several improvements in the surgical operation of hepatectomy[J]. Chin J Surg,1964, 12(8): 717-721.(in Chinese)
夏穗生, 裘法祖. 肝切除手术操作的若干改进[J]. 中华外科杂志, 1964, 12(8): 717-721.
[3]WU MC, ZHANG WH, HU HK, et al. Diagnosis and surgical treatment of primary liver cancer[J]. Med J Chin PLA, 1964, 1(1): 16-18.(in Chinese)
吴孟超, 张晚华, 胡宏楷, 等. 原发性肝癌的诊断及外科治疗[J] . 解放军医学杂志, 1964, 1(1): 16-18.
[4]OU QJ. Experimental and clinical research on the surgical treatment of liver cancer[J]. Acad J Sun Yat-Sen Univ Med Sci, 1998, 4: 288.(in Chinese)
区庆嘉. 肝癌外科治疗实验与临床研究[J]. 中山医科大学学报, 1998, 4: 288.
[5]ZHOU XD, TANG ZY, YANG BH, et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma[J]. Cancer, 2001, 91(8): 1479-1486.
[6]The clinical staging system for liver cancer by Union for International Cancer Control[J]. Hepatobiliary Surg, 1998, 4(2): 92-93.
[7]SHEN YH, SUN HC, ZHOU J. Evaluation of liver reserve function before hepatectomy[J/CD]. Chin J Hepat Surg (Electronic Edition), 2019, 8(6): 469-472.(in Chinese)
沈英皓, 孙惠川, 周俭. 肝切除术前肝脏储备功能评估[J/CD]. 中华肝脏外科手术学电子杂志, 2019, 8(6): 469-472.
[8]LU Z, GONG WF, ZHONG JH, et al. Efficacy of different liver-volume assessment indicators in predicting post-hepatectomy hepatic failure[J]. Chin J Oncol Prev Treat, 2020, 12(1): 81-85.(in Chinese)
陆战, 龚文锋, 钟鉴宏, 等. 不同肝体积评估指标预测肝癌术后肝功能衰竭的效能分析[J]. 中国癌症防治杂志, 2020, 12(1): 81-85.
[9]WANG L, LU JP. Background, current status, and perspectives of the research on the liver-specific contrast agent superparamagnetic iron oxide[J]. Radiol Pract, 2002, 17(5): 442-445.(in Chinese)
王莉, 陆建平. 肝脏特异性对比剂超顺磁性氧化铁的研究背景、现状及展望[J]. 放射学实践, 2002, 17(5): 442-445.
[10]XU SR, CHEN RX. Research advances in the treatment of hepatic arterial infusion chemotherapy (HAIC) for hepatocellular carcinoma (HCC)[J]. Fudan Univ J(Med Sci), 2019, 46(6): 814-817.(in Chinese)
许书榕, 陈荣新. 肝动脉灌注化疗(HAIC)治疗肝细胞癌(HCC)的研究进展[J]. 复旦学报(医学版), 2019, 46(6): 814-817.
[11]LIU HJ, FENG J, YANG JJ. Research advances in the multimodality therapy for primary liver cancer based on transcatheter arterial chemoembolization[J]. J Yanan Univ(Med Sci), 2019, 17(3): 82-86.(in Chinese)
刘洪敬, 冯将, 杨建军. 以TACE为主综合治疗原发性肝癌的研究进展[J]. 延安大学学报(医学科学版), 2019, 17(3): 82-86.
[12]ITAMOTO T, NAKAHARA H, KIKUCHI S. Repeat hepatectomy for recurrent hepatocellular carcinoma[J]. Surgery, 2007, 141(5): 589-597.
[13]ZHENG SS. Development of liver transplantation in China[J/CD]. Chin J Transplant(Electronic Edition), 2019, 13(4): 259-261.(in Chinese)
郑树森. 中国肝移植的发展之路[J/CD]. 中华移植杂志(电子版), 2019, 13(4): 259-261.
[14]CHEN XP. Experience in the treatment of large hepatocellular carcinoma by hepatectomy[J]. J Hepatobiliary Surg, 1994, 2(4):193-194.(in Chinese)
陈孝平. 肝切除治疗巨大肝癌的体会[J]. 肝胆外科杂志, 1994, 2(4):193-194.
[15]XU X, YANG JY, ZHONG L, et al. A multicenter study of the application of “Hangzhou criteria” in liver transplantation for liver cancer: An analysis of 1163 cases[J]. Chin J Organ Transplant, 2013, 34(9):524-527.(in Chinese)
徐骁, 杨嘉印, 钟林, 等. 肝癌肝移植“杭州标准”的多中心应用研究——1163例报道[J].中华器官移植杂志, 2013, 34(9):524-527.
[16]ZHANG X, ZHOU J. Prognosis of patients with hepatocellular carcinoma treated with liver transplantation in accordance with Milan criteria or Hangzhou criteria[J]. J Xinxiang Med Coll, 2011, 28(5):617-618.(in Chinese)
章弦, 周杰. 肝移植符合米兰标准和符合杭州标准肝细胞癌患者预后分析[J]. 新乡医学院学报, 2011, 28(5):617-618.
[17]DONG JH. Precise surgical treatment of hepatocellular carcinoma[J/CD]. Electronic J Liver Tumor, 2014, 1(1): 20-24.(in Chinese)
董家鸿. 肝细胞癌精准外科治疗[J/CD]. 肝癌电子杂志, 2014, 1(1): 20-24.
[18]LI JT, YU YQ. Surgical approach and skill of complete resection of the caudate lobe[J]. Chin J Pract Surg, 2014, 34(8):793-795.(in Chinese)
李江涛, 于源泉. 全尾状叶肝切除手术入路及技巧[J]. 中国实用外科杂志, 2014, 34(8):793-795.
[19]TOMIMARU Y, EGUCHI H, MARUBASHI S, et al. Equivalent outcomes after anatomical and non-anatomical resection of small carcinoma in patients with preserved liver function[J]. Dig Dis Sci, 2012, 57(7): 1942-1948.
[20]WAN CD, WANG GB. Advances in treatments for primary liver cancer[J]. J Abdominal Surg, 2019, 32(1):1-6.(in Chinese)
万赤丹, 王国斌. 原发性肝癌治疗进展[J]. 腹部外科, 2019, 32(1):1-6.
[21]XU HW, LIU F, HAO XY, et al. Laparoscopically anatomical versus non-anatomical liver resection for hepatocellular carcinoma[J]. Medline, 2020, 22(1): 136-143.
[22]ZHAO H, DING WZ, WANG H, et al. Prognostic value of precise hepatic pedicle dissection in anatomical resection for patients with hepatocellular carcinoma[J]. Medicine, 2020, 99(10): 1-8.
[23]YAO SY, JIA WD, GE YS, et al. Application of indocyanine green fluorescence imaging in anatomical hepatectomy for hepatocellular carcinoma[J/CD]. Chin J Hepat Surg (Electronic Edition), 2019, 8(3): 221-225.(in Chinese)
姚舜禹, 荚卫东, 葛勇胜, 等. 吲哚氰绿荧光示踪技术在肝癌解剖性肝切除中的应用[J/CD]. 中华肝脏外科手术学电子杂志, 2019, 8(3): 221-225.
[24]FANG CH, ZHANG P, ZHOU WP, et al. Efficacy of three-dimensional visualization technology in the precision diagnosis for primary liver cancer: A retrospective multicenter study of 1665 cases in China[J]. Chin J Surg, 2020, 58(5): 375-382.(in Chinese)
方驰华, 张鹏, 周伟平, 等. 三维可视化技术用于1 665例原发性肝癌精准诊治的多中心回顾性研究[J] . 中华外科杂志, 2020, 58(5): 375-382.
[25]CULVER KW, RAN Z, WALLUVIDFE S, et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brail tumors[J]. Science, 1992, 256(2): 1550-1552.
[26]ZHOU WP, WU MC, CHEN H, et al. Laparoscopic hepatic lobectomy for the treatment of hepatic hemangioma[J]. Chin J Pract Surg, 1994, 14(11): 668.(in Chinese)
周伟平, 吴孟超, 陈汉, 等. 经腹腔镜肝叶切除术治疗肝血管瘤[J]. 中国实用外科杂志, 1994, 14(11): 668.
[27]CAI XJ, YU H, ZHENG XY, et al. Laparoscopic right hemihepatectomy: A case report[J]. Natl Med J China, 2005, 85(13): 869.(in Chinese)
蔡秀军, 虞洪, 郑雪咏, 等. 腹腔镜右半肝切除1例[J]. 中华医学杂志, 2005, 85(13): 869.
[28]JIANG S, WANG ZY, OU MR, et al. Laparoscopic versus open hepatectomy in short and long term outcomes of the hepatocellular carcinoma patients with cirrhosis: A systematic review and meta-analysis[J]. J Laparoendosc Adv Surg Tech A, 2019, 29(5): 643-654.
[29]SHANG HT, BAO JH, ZHANG XB, et al. Comparison of clinical efficacy and complications between laparoscopic partial and open partial hepatectomy for liver carcinoma: A meta-analysis[J]. J Laparoendosc Adv Surg Tech A, 2019, 29(2): 225-232.
[30]YOON YI, KIM KH, CHO HD, et al. Long-term perioperative outcomes of pure laparoscopic liver resection versus open liver resection for hepatocellular carcinoma: A retrospective study[J]. Surg Endosc, 2020, 34(2): 796-805.
[31]LEI GL, LI YY, LI Z, et al. Clinical effects of laparoscopic and open hepatectomy for hepatocellular carcinoma[J]. J Hepatopancreatobiliary Surg, 2020, 32(5): 280-285.(in Chinese)
雷光林, 李媛媛, 李智, 等. 腹腔镜肝切除术与开腹肝切除术治疗肝细胞癌的疗效评估[J]. 肝胆胰外科杂志, 2020, 32(5): 280-285.
[32]ASMA S, PETER N, RAVI M, et al. Evaluating the learning curve for laparoscopic liver resection: A comparative study between standard and learning curve CUSUM[J]. HPB (Oxford), 2019, 21(11): 1505-1512.
[33]CHEN YJ, CHEN J. Technical essentials of laparoscopic right hepatectomy: Surgical progress standardization[J]. Chin J Pract Surg, 2017, 37(5): 481-485.(in Chinese)
陈亚进, 陈捷. 腹腔镜右半肝切除术的技术要领——手术流程的标准化[J]. 中国实用外科杂志, 2017, 37(5): 481-485.
[34]PACE C, NARDONE V, ROMA S, et al. Evaluation of contrast-enhanced intraoperative ultrasound in the detection and management of liver lesions in patients with hepatocellular carcinoma[J]. J Oncol, 2019, 2019: 6089340.
[35]AMADO NAM, SNCHEZ FM, RAMREZ GJ, et al. Value of intraoperative ultrasound with conventional probes and its usefulness in surgical and therapeutic management of patients[J]. Radiologia, 2017, 59(6): 516-522.
[36]SANTAMBROGIO R, CIGALA C, BARABINO M, et al. Intraoperative ultrasound for prediction of hepatocellular carcinoma biological behaviour: Prospective comparison with pathology[J]. Liver Int, 2018, 38(2): 312-320.
[37]ARITA J, TAKAHASHI M, HATA S, et al. Usefulness of contrast-enhanced intraoperative ultrasound using Sonazoid in patients with hepatocellular carcinoma[J]. Ann Surg, 2011, 254(6): 992-999.
[38]FANG CH, TAO HS, YANG J, et al. Impact of three-dimensional reconstruction technique in the operation planning of centrally located hepatocellular carcinoma[J]. J Am Coll Surg, 2015, 220(1): 28-37.
[39]ROSSI G, TARASCONI A, BAIOCCHI G, et al. Fluorescence guided surgery in liver tumors: Applications and advantages[J]. Acta Biomed, 2018, 89(9-S): 135-140.
[40]SHINGO S, SEIJI O, KAZUHIRO O, et al. Macro-and microscopic findings of ICG fluorescence in liver tumors[J]. World J Surg Oncol, 2015, 13: 198-206.
[41]ISHIZAWA T, FUKUSHIMA N, SHIBAHARA J, et al. Real-time identification of liver cancers by using indocyanine green fluorescent imaging[J]. Cancer, 2009, 115(11): 2491-2504.
[42]ISHIZAWA T, SAIURA A, KOKUDO N. Clinical application of indocyanine green-fluorescence imaging during hepatectomy[J]. Hepatobiliary Surg Nutr, 2016, 5(4): 322-328.
[43]GUGLIELMI A, RUZZENENTE A, CONCI S, et al. How much remnant is enough in liver resection?[J]. Dig Surg, 2012, 29(1): 6-17.
[44]ABDALLA EK, ADAM R, BILCHIK AJ, et al, Improving resectability of hepatic colorectal metastases: Expert consensus statement[J]. Ann Surg Oncol, 2006, 13(10):1271-1280.
[45]THIRUNAVUKARASU P, ALOIA TA. Preoperative assessment and optimization of the future liver remnant[J]. Surg Clin North Am, 2016, 96(2): 197-205.
[46]CROOME KP, HERNANDEZ-ALEJANDRO R, PARKER M, et al. Is the liver kinetic growth rate in ALPPS unprecedented when compared with PVE and donor liver transplant? A multicentre analysisi[J]. HPB(Oxford), 2015, 17(6): 477-484.
[47]LIU YY, LIU XX. Comments on associating liver partition and portal vein ligation for staged hepatectomy[J]. Chin J Dig Surg, 2013, 12(7): 481-484.(in Chinese)
刘允怡, 刘晓欣. 对“联合肝脏离断和门静脉结扎的二步肝切除术”的述评[J]. 中华消化外科杂志, 2013, 12(7): 481-484.
[48]ALOIA TA, VAUTHEY JN. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): What is gained and what is lost?[J]. Ann Surg, 2012, 256(3): e9-e19.
[49]KANG D, SCHADDE E. Hypertrophy and liver function in ALPPS: Correlation with morbidity and mortality[J]. Visc Med, 2017, 33(6): 426-433.
[50]GALL TM, SODERGREN MH, FRAMPTON AE, et al. Radio-frequency-assisted liver partition with portal vein ligation (RALPP) for liver regeneration[J]. Ann Surg, 2015, 261(2): e45-e46.
[51]CHEN YJ, HUANG PB, WANG J. Key issues in associating liver partition and portal vein ligation for staged hepatectomy[J]. J Surg Concepts Pract, 2016, 21(3): 200-203.(in Chinese)
陈亚进, 黄拼搏, 王捷. 联合肝脏离断和门静脉结扎二步肝切除术焦点问题的探讨[J]. 外科理论与实践, 2016, 21(3): 200-203.
[52]CAO J, ZHANG HW, ZHANG L, et al. Laparoscopic-assisted associating liver partition and portal vein ligation for staged hepatectomy for primary liver cancer[J]. Chin J Pract Surg, 2014, 34(1): 77-80.(in Chinese)
曹君, 张红卫, 张磊, 等. 腹腔镜辅助联合肝脏离断和门静脉结扎二步肝切除术治疗原发性肝癌可行性研究[J]. 中华实用外科杂志, 2014, 34(1): 77-80.
[53]HUANG ZJ, CAO J, LI WD, et al. Laparoscopic associating liver partition and portal vein ligation for staged hepatectomy for advanced hepatocellular carcinoma with cirrhosis: A report of 7 cases[J]. Chin J Pract Surg, 2016, 36(1): 102-110.(in Chinese)
黄泽坚, 曹君, 李闻达, 等. 腹腔镜辅助联合肝脏离断和门静脉结扎的二期肝切除术治疗伴有轻-中度肝硬化的原发性肝细胞癌(附7例报告)[J]. 中华实用外科杂志, 2016, 36(1): 102-110.
[54]CHEN YJ, CAO J. Variations and adaptations of associating liver partition and portal vein ligation for staged hepatectomy with the guidance of damage control surgery[J]. Chin J Dig Surg, 2016, 15(5): 431-437.(in Chinese)
陈亚进, 曹君. 损伤控制理念下联合肝脏离断和门静脉结扎二步肝切除术手术方式改进[J]. 中华消化外科杂志, 2016, 15(5): 431-437.
[55]de SANTIBAES E, ALVAREZ FA, ARDILES V, et al. Inverting the ALPPS paradigm by minimizing first stage impact: The Mini-ALPPS technique[J]. Langenbecks Arch Surg, 2016, 401: 557-563.
[56]JUNG SM, JANG JW, YOU CR, et al. Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases[J]. J Gastroenterol Hepatol, 2012, 27(4): 684-689.
[57]MAO K, YAN Y, ZHANG J, et al. The impact of liver resection on survival outcomes of hepatocellular carcinoma patients with extrahepatic metastases: A propensity score matching study[J]. Cancer Med, 2018, 7(9): 4475-4484.
[58]HU Z, HUANG P, ZHOU Z, et al. Aggressive intrahepatic therapies for synchronous hepatocellular carcinoma with pulmonary metastasis[J]. Clin Transl Oncol, 2018, 20(6): 729-739.
[59]BRUIX J, REIG M, SHERMAN M. Evidence-based diagnosis,staging, and treatment of patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 150(4): 835-853.